SCHEMBL25525581

SCHEMBL25525581

COc1cccc(C(=N)NC(=O)c2ccc(=O)n(Cc3cccnc3)c2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.47
LMNA P02545 1/20 0.47
ALDH1A1 P00352 2/20 0.46
RAB9A P51151 1/20 0.46
TDP1 Q9NUW8 2/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
MAPT P10636 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
GAA P10253 1/20 0.46
BRD4 O60885 2/20 0.46
BRD2 P25440 1/20 0.46
BRD3 Q15059 1/20 0.46
BRDT Q58F21 1/20 0.46
KLKB1 P03952 1/20 0.44
KDM4E B2RXH2 1/20 0.44
GFER P55789 1/20 0.44
PTAFR P25105 1/20 0.44
TSHR P16473 1/20 0.44
ABCB1 P08183 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25525568 0.88 LMNA (0.51) LMNAALDH1A1MAPTBRD4BRD2
SCHEMBL25525580 0.86 TP53 (0.46) LMNAALDH1A1RAB9AKMT2AMAPT
SCHEMBL25525564 0.86 ALDH1A1 (0.53) SMN1; SMN2LMNAALDH1A1RAB9AMEN1
SCHEMBL25525591 0.85 BRD4 (0.57) SMN1; SMN2LMNAALDH1A1RAB9AKMT2A
SCHEMBL25525585 0.83 MAPT (0.49) LMNAALDH1A1KMT2AMAPTGAA
SCHEMBL25525579 0.82 BRD4 (0.49) LMNAALDH1A1MAPTL3MBTL1GAA
SCHEMBL25525582 0.80 BRD4 (0.48) SMN1; SMN2LMNAALDH1A1RAB9AKMT2A
SCHEMBL25525592 0.77 BRD4 (0.52) SMN1; SMN2LMNAALDH1A1RAB9AKMT2A
SCHEMBL25525565 0.77 MAPT (0.49) SMN1; SMN2LMNAALDH1A1RAB9AMAPT
SCHEMBL25525572 0.77 MAPT (0.48) SMN1; SMN2LMNAALDH1A1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159513-A1 PYRIDAZINONE COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISEASES EDGEWISE THERAPEUTICS, INC. 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159513-A1 PYRIDAZINONE COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISEASES IL6, IL1B, IL1RN SMN1; SMN2 6/4885LMNA 397/4885ALDH1A1 370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.